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Summary
Breast cancers may evade the growth-inhibitory action of TGFb by accumulating defects of unknown nature that selectively
eliminate cytostatic gene responses. We found the transcription factor C/EBPb to be essential for TGFb induction of the cell
cycle inhibitor p15INK4b by a FoxO-Smad complex and repression of c-MYC by an E2F4/5-Smad complex in human epithelial
cells. These cytostatic responses are selectively missing in metastatic breast cancer cells from half of the patients that we
tested. The basis for this loss was traced to an excess of the C/EBPb inhibitory isoform LIP. We suggest that C/EBPb plays
a key role in the coordination of TGFb cytostatic gene responses, and itsmalfunctionmay trigger evasion of these responses
in breast cancer.Introduction
Transforming growth factor-b (TGFb) is the most potent and
widespread growth-inhibitory cytokine known in mammals
(Bierie and Moses, 2006; Roberts and Wakefield, 2003; Siegel
et al., 2003). Its cytostatic effect is based on elevating the
expression of the CDK inhibitors p15INK4b, p21CIP1, or
p57KIP2 and concurrently repressing MYC growth-promoting
factors and ID antidifferentiation factors (Siegel and Massague´,
2003). Cancer cells may gain a selective advantage from losing
these responses. Indeed, resistance to the growth-inhibitory ac-
tion of TGFb is considered a hallmark of cancer (Hanahan and
Weinberg, 2000).
TGFb is also a paradigm of functional versatility, controlling
not only cell proliferation but also differentiation and stress
responses, the production of secretory factors and matrix pro-
teins, and the activity of many signaling pathways. This pleiotro-
pic action has important implications in cancer. In a fraction of
gastrointestinal and pancreatic cancers and a small proportion
of other cancers, TGFb resistance results frommutations that in-
activate the TGFb receptors or their Smad signal transducers
(Derynck et al., 2001; Massague´ et al., 2000). But TGFb cyto-
static gene responses may also be selectively eliminated byCANCER CELL 10, 203–214, SEPTEMBER 2006 ª2006 ELSEVIER INC. DOdownstream defects of unknown nature that spare receptor
and Smad functions. When this occurs, tumor cells may use
their remaining TGFb responses to their advantage during inva-
sion (Derynck et al., 2001; Roberts and Wakefield, 2003), eva-
sion of immune surveillance (Gorelik and Flavell, 2002; Thomas
and Massague´, 2005; Wojtowicz-Praga, 2003), and metastatic
colonization (Dumont and Arteaga, 2003; Kang et al., 2005;
Roberts and Wakefield, 2003; Siegel and Massague´, 2003).
To trigger gene responses, the TGFb receptor complex phos-
phorylates Smad2 and Smad3 transcription factors, which then
translocate into the nucleus, bind Smad4, and associate with di-
verse DNA binding cofactors to target specific genes for regula-
tion (Massague´ et al., 2005). Repression of c-MYC and ID1 is me-
diated by Smad complexes with E2F4/5 (Chen et al., 2002;
Frederick et al., 2004) and ATF3 (Kang et al., 2003a), respectively,
whereas Smad complexes with FoxO factors (FoxO1, FoxO3,
and FoxO4) mediate the induction of p21CIP1 (Seoane et al.,
2004) and p15INK4b (Gomis et al., 2006). FoxO factors are critical
players in cellular growth-inhibitory responses to stress, and de-
terminants of organismal longevity (Brunet et al., 2004; Greer and
Brunet, 2005; Lee et al., 2003; Libina et al., 2003).
Understanding how the selective elimination of TGFb cyto-
static responses is achieved in cancer has remained an elusiveS I G N I F I C A N C E
Tumor cells frequently evade the growth-inhibitory action of the cytokine TGFb, thus gainingoneof the hallmarks of cancer.We suggest
amechanistic explanation for this process in breast cancer.We found that twocritical gene responses for the growth-inhibitory effect of
TGFb require the transcription factor C/EBPb. An excess of the C/EBPb inhibitor LIP appears to selectively limit these gene responses
in metastatic cells from certain breast cancer patients. Thus, C/EBPb may constitute a weak link in the TGFb pathway, which breast
cancer cells may exploit to skirt growth inhibition. Interventions that would restore C/EBPb activity may resensitize these cells to the
tumor-suppressive action of TGFb.I 10.1016/j.ccr.2006.07.019 203
A R T I C L Egoal. Loss of the ultimate effector of cytostatic inputs, the tumor
suppressor Rb, confers resistance to TGFb (Herrera et al., 1996;
Laiho et al., 1990), but loss of other interconnected tumor sup-
pressors such as p53, p16Ink4a, ARF, or p27Kip1 does not. Be-
cause of functional redundancies, TGFb remains a potent
growth inhibitor in cells that lack p15Ink4b (Latres et al., 2000)
or the c-Myc response (Chen et al., 2002). However, breast can-
cer cell lines with a combined loss of these two gene responses
evade the cytostatic action of TGFb (Chen et al., 2001).
To identify links in the TGFb cytostatic program that could be
prone to disruption in cancer, we investigated the organization
of Smad-dependent transcriptional events in epithelial cells, fo-
cusing particularly on cytostatic gene responses. An analysis of
genes that are controlled by the FoxO-Smad combination has
revealed that some of these genes, including p15INK4b, addi-
tionally require C/EBPb for their response to TGFb. Moreover,
c-MYC repression also shares this requirement. C/EBPb thus
emerges as a key player in the TGFb cytostatic program. C/
EBPb is amember of the basic leucine zipper family of transcrip-
tional regulators and plays important roles in cell proliferation,
differentiation, and oncogene-induced senescence through
both positive and negative effects on gene expression (Begay
et al., 2004; Grimm and Rosen, 2003; McKnight, 2001). Defects
in C/EBPb favor tumor progression in mouse models (Sebastian
et al., 2005), and excess of the C/EBPb inhibitory isoform LIP is
implicated in breast cancer progression in mice (Zahnow et al.,
2001) and humans (Milde-Langosch et al., 2003; Raught et al.,
1996; Zahnow et al., 1997). Based on these clues, we went on
to find that a high level of LIP is linked to a loss of TGFb-depen-
dent cytostatic responses in metastatic cells from breast cancer
patients.
Results
Role of C/EBPb in the induction of CDK
inhibitors by TGFb
The p21CIP1 gene response ismediated by Smad3 and Sma4 in
combination with FoxO factors (FoxO1, FoxO3, or FoxO4)
(Seoane et al., 2004). p15INK4b was found to also be part of
the subset of TGFb target genes that are controlled by the
Smad/FoxO combination (Gomis et al., 2006; and see below).
In addition, p15INK4b and p21CIP1 share the property of being
inhibited by binding of a c-Myc-Miz1 complex to their proximal
promoter region (Seoane et al., 2001, 2002; Staller et al., 2001)
(Figure 1A). However, the Smad-responsive regions of the
p15INK4b and p21CIP1 promoters show some differences.
The Smad binding region of the p21CIP1 promoter comprises
one forkhead binding element (FBHE) followed by three closely
spaced Smad binding elements (SBEs) (Figure 1A) (Seoane
et al., 2004). In the TGFb-responsive region of the distal
p15INK4b promoter (Seoane et al., 2001), we observed two sep-
arate SBEs, one flanked by a FBHE, forming the ‘‘Smad binding
region 1’’ (SBR1), and the other flanked by a consensus binding
site for C/EBPb (SBR2; Figure 1A). All these elements are con-
served between human and mouse (Figure 1A, bottom). Thus,
the presence of a C/EBPb binding element near an SBE distin-
guished the p15INK4b promoter from the p21CIP1 promoter
and was investigated further.
The human C/EBPb locus encodes three isoforms, LAP1,
LAP2, and LIP, by alternative usage of different start codons (re-
fer to Figure 1E). LAP1 and LAP2 contain a dimerization and204DNA binding domain and a transcription regulatory domain
and function as dimeric transcriptional regulators. LIP lacks
the regulatory domain and functions as a dominant-negative in-
hibitor of LAPs (Grimm and Rosen, 2003; Zahnow, 2002). To in-
vestigate the role of C/EBPb in the p15INK4b response, we used
a transcriptional reporter construct based on the 2751/+70 re-
gion of the human p15INK4b promoter. This construct was re-
sponsive to TGFb in wild-type but not FoxO-depleted HaCaT
cells (Figure 1B). The activity of this construct was increased
by overexpression of FoxO and LAP2, particularly when com-
bined with Smad3 overexpression (Figure 1B). The LAP2 con-
struct used in these experiments contains a conservative ATG
to ATC mutation (Met to Ile) that eliminates the LIP translation
start site, thus averting ectopic expression of LIP (Descombes
and Schibler, 1991).
When placed in front of an adenovirus E1b minimal promoter,
the isolated SBR1 (2538/2506) segment showed increased ac-
tivity in the presence of overexpressed FoxO3 but not LAP2
(Figure 1C, left panel). A similar response was obtained with
the Smad binding region of p21CIP1 (Figure 1C, middle panel).
In contrast, the p15INK4b SBR2 (2443/2385) segment showed
increased activity in the presence of ectopic LAP2 but not
FoxO3 (Figure 1C, right panel). Another family member, C/
EBPa, increased the basal activity of the SBR2 construct but
conferred little response to TGFb, whereas C/EBPg had no ef-
fect (Figure 1D). Mutations that disrupt the SBE or C/EBPb sites
in the SBR2 abrogated its response to TGFb and LAP2 but not
a TGFb-independent response to C/EBPa (Figure 1D). Among
different C/EBPb isoforms, LAP2, but not LAP1 or LIP, mediated
SBR2 activation (Figure 1E). Furthermore, overexpression of LIP
abolished the effects of LAP2, LAP2 plus Smads, and TGFb
(Figure 1E).
C/EBPb interaction with the p15INK4b promoter
Evidence of a TGFb-directed interaction of the endogenous pro-
teins with the p15INK4b promoter was obtained by chromatin
immunoprecipitation (ChIP) analysis of relevant promoter re-
gions (Figure 2A). TGFb addition to cells rapidly induced the
binding of Smad2/3, FoxO3, and C/EBPb to the SBR1/2 region
of the promoter (Figure 2B), as well as the binding of Smad4 and
FoxOs 1 and 4 (data not shown). Note that the antibodies do not
distinguish between Smad2 and Smad3. This binding was not
observed with the proximal promoter region of p15INK4b, which
served as an internal control (Figure 2B). This proximal promoter
region binds c-Myc, which disappeared on TGFb stimulation
(Figure 2B; refer also to Figure 1A).
To verify that LAP2 can bind to the distal p15INK4b promoter
region, we ectopically expressed Flag epitope-tagged proteins
of interest in HaCaT cells. ChIP assays demonstrated a
TGFb-dependent binding of Flag-LAP2, Flag-Smad3, and
Flag-FoxO3 to the distal region, but not the proximal region (Fig-
ure 2C). Coimmunoprecipitation assays demonstrated a TGFb-
dependent interaction between endogenousSmad4 andC/EBPb
as well as Smad2/3 (Figure 2D). An interaction between
HA-tagged LAP2 and Flag-tagged Smads 2, 3, and 4, but not
Flag-Smad1, was observed in transfected COS-1 cells (data
not shown). Also, endogenous and direct interaction between
Smads and C/EBP family members has been reported (Choy
and Derynck, 2003). Taken together, these results suggest to
us that Smad, FoxO, and C/EBPb target the SBR1/SBR2 regionCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 1. Smad, FoxO, and C/EBPb transactivate p15INK4b
A: Graphic comparison of the p15INK4b promoter with the p21CIP1 promoter and the dual TGFb input. The nucleotide sequence of the human and mouse
p15INK4b Smad binding regions (SBR1 and SBR2) containing binding elements for Smad (SBE, orange), Forkhead (FHBE, green), and C/EBPb (C/EBPbBE, blue)
are shown.
B: HaCaT cells were transfected with transcriptional reporter construct based on the2751/+70 p15INK4b promoter region driving firefly luciferase expression.
Where indicated, the cells were cotransfected with siRNA against FoxOs, or with vectors encoding FoxO3, C/EBPb LAP2, or Smad3. Cells were then treated
with TGFb for 20 hr, and luciferase activity was determined. Luciferase activity was normalized based on a cotransfected CMV-renilla luciferase vector. Data
are mean 6 SD (n = 3).
C–E:HaCaT cells transfected with luciferase reporter constructs driven by 43multimers of p15SBR1, p15SBR2, and p21SBR (C), 43multimers of p15SBR2 and the
indicated mutations (D), or 43 multimers of p15SBR2 (E). FoxO, C/EBPb, or Smad expression vectors were cotransfected with the reporter constructs as indi-
cated. Cells were then treated as in B.of the p15INK4b promoter to mediate TGFb-dependent tran-
scriptional activation.
C/EBPb couples p15INK4b activation and c-MYC
repression by TGFb
To determine whether C/EBPb is required for p15INK4b induc-
tion by TGFb, we transfected HaCaT cells with a LIP expression
vector. LIP overexpression markedly blunted the p15INK4b re-
sponse at the mRNA and protein levels, with little effect on the
p21CIP1 response (Figure 3A). In a separate approach, we
also tested the effect of the stable knockdown of C/EBPb by
means of a shRNA vector (Figures 3B and 3C). C/EBPb knock-
down sharply inhibited the p15INK4b response with little effect
on the p21CIP1 response (Figure 3D).
Together with the induction of CDK inhibitors, the transcrip-
tional repression of c-MYC is an important part of the growth-
inhibitory response of epithelial and hematopoietic cells to
TGFb (Scandura et al., 2004; Siegel and Massague´, 2003). TheCANCER CELL SEPTEMBER 2006induction of p15INK4b and p21CIP1 and the repression of c-
MYC are concurrent events in HaCaT cells and are mediated
by distinct Smad complexes. Given the opposite nature of the
c-MYC and p15INK4b responses, we were surprised to find
that both the overexpression of LIP (Figure 3A) and the knock-
down of C/EBPb (Figure 3D) inhibited c-MYC repression by
TGFb in HaCaT cells.
Repression of c-MYC is mediated by the binding of a tran-
scriptional repression complex containing Smad, E2F4/5, and
p107 to the ‘‘TGFb inhibitory element’’ (TIE) in the proximal pro-
moter region (Chen et al., 2002; Frederick et al., 2004). Enforced
overexpression of LIP increased the basal activity of this c-MYC
promoter region in transcriptional assays and blunted the
transcriptional repression of this promoter caused by TGFb
(Figure 4A). ChIP analysis demonstrated binding of endogenous
C/EBPb to the TIE region under basal conditions (Figure 4B),
which is in agreement with a recent report (Sebastian et al.,
2005). TGFb addition caused a small increase in this binding205
A R T I C L EFigure 2. TGFb-inducible binding of Smad, FoxO, and C/EBPb to the p15INK4b promoter
A: A schematic representation of the human p15INK4b promoter regions amplified in ChIP assays. The SBEs (orange), FHBE (green), C/EBPbBE (blue), and INR
(gray) are indicated.
B: HaCaT cells were incubated with or without TGFb for 90 min and subjected to ChIP assays with the indicated antibodies and PCR primers. The proximal
region of the p15INK4b promoter was used as a negative control.
C: HaCaT cells were transfected with the indicated Flag-tagged expression vectors and cultured for 24 hr. Cells were then incubated with or without TGFb for
90 min and subjected to ChIP assays with anti-Flag antibodies and the indicated PCR primers.
D: HaCaT cells were treated with or without TGFb for 90 min, and lysates were immunoprecipitated with the indicated antibodies and then subjected to
immunoblotting with anti-Smad4 antibody.(Figure 4B) together with a previously reported increase in the
binding of Smad2/3 and E2F4 to this region (Chen et al., 2002).
Previous work has shown that depriving cells of either the
p15Ink4b response (Latres et al., 2000) or the c-Myc response
to TGFb (Chen et al., 2002) does not diminish the growth-inhib-
itory effect of TGFb. However, together with the blunting of both
gene responses, the enforced overexpression of LIP in HaCat
cells caused an attenuation of the growth-inhibitory effect of
TGFb (Figure 4C). The knockdown of C/EBPb completely
abolished the growth-inhibitory effect of TGFb (Figure 4D).206Collectively, these results show that C/EBPb function is required
for two gene responses—p15INK4b induction and c-MYC
repression—that are central to the cytostatic action of TGFb.
A LIP/LAP imbalance in TGFb-resistant
breast cancer cells
In light of these clues and previous work linking high LIP expres-
sion to breast cancer progression (Milde-Langosch et al., 2003;
Raught et al., 1996; Zahnow et al., 1997), we wondered whether
evasion of TGFb cytostatic action in breast cancers may beFigure 3. Requirement of C/EBPb for cytostatic TGFb gene responses
A:HaCaT cells infected with a retroviral vector encoding the LIP isoform of C/EBPbor an empty retrovirus vector were incubated in the presence or absence of
TGFb for 3 hr. Total RNA was subjected to Northern blot analysis using the indicated probes. Whole-cell extracts from cells incubated with or without TGFb for
5 hr were subjected to immunoblotting with the indicated antibodies.
B: Total RNA from control and C/EBPb-depleted HaCaT cells was subjected to Northern blot analysis using the indicated probes.
C: Immunoblots with the indicated antibodies were performed on whole-cell extracts from control and C/EBPb-depleted HaCaT cells.
D: Control and C/EBPb-depleted HaCaT cells were treated with or without TGFb for 3 hr. Total RNA was subjected to Northern blot analysis using the indicated
probes. Whole-cell extracts were treated as in A.CANCER CELL SEPTEMBER 2006
A R T I C L EFigure 4. Requirement of C/EBPb for the TGFb
growth-inhibitory response
A:HaCaT cells transfected with a firefly luciferase
reporter construct driven by the TGFb-responsive
region of the c-Myc promoter plus a LIP expres-
sion vector as indicated were treated with
TGFb for 20 hr, and luciferase activity was deter-
mined. TGFb-responsive luciferase activity was
normalized against the activity of cotransfected
renilla luciferase driven by a constitutive pro-
moter. Data are mean 6 SD (n = 3).
B: HaCaT cells were incubated with or without
TGFb for 90 min and subjected to ChIP assays
with the indicated antibodies and PCR primers
for the proximal region of the myc promoter.
The b-ACTIN promoter was used as a negative
control.
C and D: Growth curves of control and Lip-over-
expressing HaCaT cells (C) or control and
C/EBPb-depleted HaCaT cells (D) with or without
TGFb. Data are average of triplicated cell
counts 6 SD.linked to defects in C/EBPb function. We investigated this pos-
sibility in malignant cells that were freshly obtained from the
pleural fluid of patients with advanced breast cancer. These pa-
tients were undergoing therapeutic procedures as part of their
routine clinical management at our institution. All samples
were obtained and used under institutionally approved proto-
cols. The cellular fraction from these fluids was enriched for car-
cinoma cells by positive selection using the epithelial cell marker
EpCAM (Al-Hajj et al., 2003; Kielhorn et al., 2002; Latza et al.,
1990). Of 42 samples that were collected and treated in this
manner, eight yielded sufficient malignant cells for study
(Table 1). These cells were propagated in culture for no more
than 2 weeks prior to being used in experiments. Incubation
with TGFb led to the rapid accumulation of receptor-phosphor-
ylated Smad2 and induction of the Smad target geneCTGF in all
these samples (Figure 5A, middle panels), indicating that meta-
static breast cancer cells frequently retain TGFb receptor and
Smad functions.
Four of the samples (CN19, CN30, CN43, and CN47) showed
downregulation of c-MYC and induction of p15INK4b and
p21CIP1 in response to TGFb (Figure 5A, top panels). These
gene responses were accompanied by approximately 50% inhi-
bition in the rate of DNA synthesis by TGFb (Figure 5A, bottom
panels). However, the other four samples showed defects inCANCER CELL SEPTEMBER 2006their cytostatic response to TGFb. Depending on the specimen,
these defects included an absence of p15INK4b response (sam-
ple CN34); absence of p15INK4b and c-MYC responses (sam-
ples CN37 and CN41); or absence of p15INK4b, p21CIP1, and
c-MYC responses (sample CN46). The drop in DNA synthesis
caused by TGFb in these four samples barely surpassed 25%,
and it was completely absent in sample CN46 (Figure 5A,
bottom).
Western immunoblotting analysis of C/EBPb products re-
vealed striking differences in the level of LIP in these samples.
LIP levels were at least 4-fold higher in the four samples that
were defective in TGFb cytostatic responses than in the TGFb-
sensitive samples (Figure 5B). When normalized to molar ratios,
LIP was in molar excess over LAP in the samples lacking c-MYC
and p15INK4b responses, and LAP was in molar excess in the
samples with normal TGFb responses. Thus, an inverse correla-
tion exists between the LIP:LAP ratio in these breast cancer cells
and their growth-inhibitory responsiveness to TGFb (Figure 5C).
To investigate whether the defect in cytostatic TGFb gene re-
sponses in breast cancer samples was accompanied by alter-
ations in other TGFb gene responses, we determined the level
of expression of genes of interest in three LIP-rich samples
(CN34, CN37, and CN41) and three samples with low LIP levels
(CN19, CN43, and CN47). All six samples were derived fromTable 1. Clinicopathologic data of the primary tumors and metastases corresponding to the patients whose pleural fluid was used as a source of tumor cells
in this study
Pleural sample Type Primary tumor size Grade ER PR HER2 Metastasis sitesa
S19 ductal 3.5 cm I/III + + + Pl, Lu, LN
S30 ductal 0.7 cm III/III 2 2 + Pl, LN, CW, Me, Ad
S34 ductal 2.5 cm III/III + 2 NA Pl, Lu, LN, Bo
S37 ductal 3.2 cm III/III + + ++ Pl, Lu, LN, Br, Li
S41 ductal 4.5 cm, 6.5 cmb II/III + + ++ Pl, Lu?, Br, Bo, CW
S43 ductal 1.3 cm II/III + + + Pl, Lu, Li, Bo
S46 ductal 0.7–3.8 cm III/III 2 2 +++ Pl, Bo, ST, LN
S47 lobular 2 cm NA + + + Pl, Lu, Li, LN, Ca, Co
aPl, pleural; Lu, lung; LN, lymph nodes; CW, chest wall; Me, mesentery; Ad, adrenal; Bo, bone; Br, brain; Li, liver; ST, soft tissue; Ca, perinoteal carcinomatosis; Co,
colon.
bBilateral tumor.207
A R T I C L EFigure 5. Evasion of TGFb cytostatic responses in
metastatic breast cancer cells is linked to LIP/LAP
imbalance
A: EpCAM+ cells sorted from pleural effusion
fluids from breast cancer patients were cultured
in the presence or absence of TGFb for 3 hr. Total
RNA was subjected to Northern blot analysis us-
ing the indicated probes. Whole-cell extracts
were probed with the indicated antibodies.
Bottom: cells were treated for 20 hr with the indi-
cated concentrations of TGFband pulsed for 6 hr
with 125I-deoxyuridine. 125I-dU incorporation was
determined, and the data are plotted as per-
centage incorporation relative to control cells
that received no TGFb. Data are mean 6 SD
(n = 3).
B: Whole-cell extracts from the cell samples
described in A were probed with the indicated
antibodies.
C: The relative inhibition of 125I-dU incorporation
by 100 pM TGFb is plotted against the LIP:LAP
molar ratio in each cell sample described in B.patients with an initial diagnosis of ER+ ductal carcinoma (Table
1). In addition to lacking the p15INK4b response, the three LIP-
rich samples lacked GADD45A, LEMD3, and IER3 responses
(Figure 6). Inductions of GADD45A and LEMD3 by TGFb have
been identified as a FoxO- and C/EBPb-dependent gene re-
sponses in human epithelial cells (Gomis et al., 2006). Induction
of SMAD7, PAI1, IL11, SGK, p21CIP1,GADD45B, and CTGF by
TGFb was observed in most samples in both groups. However,
SMAD7, PAI-1, and GADD45B were induced to lower levels in
the LIP-rich group (Figure 6). In contrast, these three samples
show a remarkably robust induction of IL11, which has been im-
plicated in bone metastasis (Kang et al., 2003b, 2005). Collec-
tively, these results show that a high level of LIP in metastatic
breast cancer cells was associated with an attenuation of
p15INK4b induction and other C/EBPb-dependent responses,
and an accentuation of IL11 induction in response to TGFb.
LAP restores TGFb cytostatic responses in resistant
breast cancer cells
To investigate the relationship between a high LIP:LAP ratio and
a defective TGFb cytostatic response, we sought to normalize208this ratio in samples CN37 and CN41. We chose these samples
because they are defective in both the c-MYC and p15INK4b re-
sponses to TGFb but retain the p21CIP1 response (refer to
Figure 5B). As RNAi-mediated depletion of LIP is not feasible
without also targeting LAP, we decreased the LIP:LAP ratio by
means of a retroviral vector encoding human LAP2. Transduc-
tion of CN37 and CN41 cells with a LAP2 vector brought the
LIP:LAP molar ratio from 1.8 and 1.6 to 0.4 and 0.3, respectively
(Figure 7A). In CN41cells, LAP2 overexpression caused a repro-
ducible decrease in the basal level of c-MYC mRNA and an in-
crease in the basal level of p21CIP1, without evidence of
Smad2 phosphorylation by autocrine TGFb (Figure 7A).
LAP2 expression conferred to both samples the ability to
downregulate c-MYC in response to TGFb (Figure 7A). Quantita-
tion of normalized c-MYCmRNA levels, from three independent
experiments, demonstrated a TGFb-induced decrease in c-
MYC levels down to 46% and 68% of basal levels in CN37
and CN41 cells, respectively (Figure 7A). LAP2 additionally re-
stored the p15INK4b response to TGFb, as well as the response
of other C/EBPb-dependent members of the FoxO-Smad-
responsive group, GADD45A, LEMD3, and CDC42EP3 (GomisFigure 6. TGFb responses in breast cancer cells
Expression levels of different TGFb target genes in
six primary breast cancer cell samples that were
incubated with or without TGFb for 3 hr and ana-
lyzed by qRT-PCR using primers for the indicated
genes.CANCER CELL SEPTEMBER 2006
A R T I C L EFigure 7. Lap restores TGFb cytostatic responses in resistant breast cancer cells
A: Tumor cell samples CN37 and CN41 were infected with a retroviral vector encoding the LAP2 C/EBPb isoform or a GFP fusion protein as control. Transduced
cells were selected for 48 hr based on a puromycin resistance marker, allowed to recover for another 24 hr, and then treated with or without TGFb for 3 hr. Total
RNA was subjected to Northern blot analysis using the indicated probes. Whole-cell extracts were probed with the indicated antibodies. c-MYC levels were
normalized against b-ACTIN and were used to calculate the TGFb fold repression. Data are mean 6 SD of three independent experiments.
B: Total RNA from sample CN37 in A was subjected to qRT-PCR analysis using the indicated probes. Data are mean 6 SD of three independent experiments.
ND, not detectable signal.
C: CN37 and CN41 cells treated as in A were then incubated for 20 hr with the indicated concentrations of TGFb and cultured in the presence of 125I-dU for an
additional 6 hr. 125I-dU incorporation into DNA was determined. Data are mean6 SD (n = 3). The 125I-dU incorporation of the 100 pM TGFbcondition compared
to controls that did not receive TGFb is indicated for each cell sample.
D: Growth in mammary fat pad (MFP) of CN37 cells stably transfected with a retroviral construct encoding firefly luciferase and also stably transfected with
control or LAP2 vector. Each curve shows tumor luminescence as a normalized photon flux emission. The mice images are representative of each group.
E: Schematic model of a set of cytostatic gene responses triggered by TGFb in keratinocytes and primary breast cancer cells. Induction of p21CIP1 and
p15INK4b are mediated a by FoxO-Smad combination, whereas repression of c-MYC is mediated by a E2F4/5-Smad combination. The p15INK4b and
c-MYC responses are enabled by the active C/EBPb isoform LAP2, which is opposed by the natural dominant-negative inhibitory isoform LIP. In metastatic
breast cancer cells with a high LIP:LAP ratio, the p15INK4b and c-MYC are cancelled. See the text for details and references.et al., 2006), as determined by qRT-PCR in CN37-LAP2
(Figure 7B). LAP2 had little or no effect on the TGFb response
of p21CIP1 (Figure 7A) and JAGGED1 (Figure 7B), which is con-
sistent with these being C/EBPb-independent FoxO-Smad
target genes. Thus, LAP2 overexpression rescued C/EBPb-de-
pendent TGFb gene responses, including cytostatic responses,
that were missing in these breast cancer cells.
LAP2 overexpression caused a significant reduction in the
proliferative activity of CN37 and CN41 cells. The rate of DNA
synthesis in LAP2-transduced CN37 and CN41 cells compared
to controls dropped by approximately 50% and 90%, respec-
tively (Figure 7C). The CN41-LAP2 cells, in particular, presented
a flat, enlarged morphology typical of senescent cells, in con-
trast to the transformed morphology of control CN41 cellsCANCER CELL SEPTEMBER 2006(data not shown). This morphology, together with the associated
drop in proliferative activity and the changes in basal c-MYC and
p21CIP1 expression induced by LAP2, is suggestive of cell
senescence. This notwithstanding, LAP2 overexpression in-
creased the cytostatic response to TGFb in CN37 cells, which
responded with an approximately 50% inhibition in the rate of
DNA synthesis (Figure 7C). Thus, restoration of a low LIP:LAP ra-
tio rescued missing C/EBPb-dependent TGFb gene responses,
including c-MYC and p15INK4b, together with a more extensive
growth-inhibitory effect of TGFb.
To determine whether LAP2 overexpression inhibited the
tumor-initiating capacity of these cells in vivo, CN37 and CN37-
LAP2 cells were transduced with a luciferase vector and
implanted in the mammary fat pads of nude mice. The bulk of209
A R T I C L Ethe inoculated cell population died off during the first 10 days af-
ter implantation, as determined by quantitative bioluminescence
imaging (Figure 7D). Over the next 80 days, CN37 cells formed
tumors in three out of eight inoculated mammary fat pads,
whereas the CN37-LAP2 cells failed to form tumors (Figure 7D).
No remaining CN37-LAP2 cells could be detected in the mam-
mary fat pads by tissue examination after sacrifice on day 80
(data not shown). Therefore, decreasing the LIP:LAP ratio not
only restored C/EBPb-dependent TGFb gene responses and
growth inhibition in the bulk tumor cell population but also
inhibited the tumor-initiating capacity of CN37 cells.
Discussion
The present results have uncovered an unexpected role of the
multifunctional transcription factor C/EBPb in the coordination
of key cytostatic gene responses to TGFb. Furthermore, our re-
sults suggest a mechanism for the selective loss of these re-
sponses inmetastatic breast cancers (summarized in Figure 7E).
C/EBPb at the core of the TGFb cytostatic program
The induction of CDK inhibitors by TGFb and the repression of
transcriptional enforcers of cell proliferation constitute, in differ-
ent combinations, the cytostatic program triggered by this cyto-
kine in epithelial and hematopoietic cells (Scandura et al., 2004;
Siegel andMassague´, 2003). The induction of p21CIP1 by TGFb
involves a FoxO binding site and three contiguous Smad sites
(Seoane et al., 2004). In contrast, here we find that the induction
of p15INK4b involves two separate Smad binding elements, one
flanked by a FoxO site and the other by a C/EBPb site. All these
sites contribute to the TGFb response. C/EBPb binds to this
region along with Smad and FoxO factors on TGFb stimulation.
C/EBPb is essential for p15INK4b induction, as demonstrated
by RNAi-mediated knockdown of C/EBPb or overexpression
of the naturally occurring C/EBPb inhibitory isoform LIP.
We found that C/EBPb is required not only for the induction of
p15INK4b but also for the repression of c-MYC. Indeed, C/EBPb
is known to have opposite effects on gene expression, depend-
ing on the target (Begay et al., 2004; Grimm and Rosen, 2003;
McKnight, 2001). Repression of c-MYC is not mediated by
FoxO-Smad but by a E2F4/5-Smad combination (Chen et al.,
2002; Frederick et al., 2004). In our ChIP assays, binding of C/
EBPb to the p15INK4b promoter is stimulated by TGFb, whereas
binding to the proximal c-MYC promoter seems to be partly
constitutive. These results argue that C/EBPb may use distinct
mechanisms to enable different gene activation and repression
responses in the Smad pathway. Ongoing work suggests that
up to one-fifth of all TGFb gene responses in keratinocytes
require C/EBPb (our unpublished data).
The requirement of C/EBPb in both p15INK4k induction and
c-MYC repression places this factor at the core of the TGFb
cytostatic program (Figure 7E). The growth-inhibitory effect of
TGFb in keratinocytes indeed is abolished by RNAi-mediated
knockdown of C/EBPb. C/EBPb is implicated in growth inhibi-
tion and terminal differentiation in some contexts but stimulates
cell proliferation in others (Begay et al., 2004; Grimm and Rosen,
2003; Lekstrom-Himes and Xanthopoulos, 1998). The basis for
these opposite effects is unknown but could reflect differences
in the LIP:LAP ratio (Zahnow et al., 2001). As shown here, the
level of LIP might be an important determinant of the respon-
siveness of human keratinocytes and breast cancer cells to210TGFb. LIP translation is controlled by the RNA binding protein
CUG-BP1 (Timchenko et al., 1999, 2001, 2005). Interestingly,
epidermal growth factor signaling leads to CUG-BP1 phosphor-
ylation and increases the LIP:LAP ratio (Baldwin et al., 2004). It
will be important in the future to more completely define the
role of C/EBPb in TGFb action and how these C/EBPb regulatory
inputs may become integrated with the Smad pathway.
C/EBPb and evasion of TGFb tumor suppression
in breast cancer
Breast cancer cells that become resistant to the growth-inhibi-
tory effects of TGFb often retain TGFb receptors and Smad
functions but have a selective loss of cytostatic gene responses.
This phenomenon was previously observed with genetically
modified mouse models and human tumor-derived cell lines
(Dumont and Arteaga, 2003; Kang et al., 2005; Roberts and
Wakefield, 2003; Siegel and Massague´, 2003). This phenome-
non has been validated in the present studies with primary met-
astatic breast cancer cells. Of eight clinical samples that we in-
vestigated, none shows defects in TGFb receptor or Smad
function. These cells responded to TGFb with Smad phosphor-
ylation and several Smad-dependent gene responses, such as
induction of CTGF, IL11, SMAD7, or p21CIP1. However, half
of these samples lacked p15INK4b and c-MYC responses and
were only weakly growth inhibited by TGFb. In samples that re-
tain the p15INK4b and c-MYC responses, TGFb inhibits prolifer-
ation by at least 50%. We do not know whether this extent of in-
hibition still represents a suboptimal response, but it certainly
defines, within these metastatic samples, a group with higher
sensitivity to cytostatic action of TGFb.
The absence of p15INK4b and c-MYC responses in some of
these primary breast cancer cells is striking for two reasons.
First, this anomaly phenocopies the defects obtained by C/
EBPb depletion or LIP overexpression in keratinocytes, Sec-
ondly, this defect coincides with the presence of a high LIP:LAP
ratio in the clinical samples that we examined. By transducing
LIP-rich breast cancer cells with a LAP2 expression vector, we
were able to recover the missing TGFb gene responses and to
decrease the tumorigenic activity of these cells. Thus, a link be-
tween a high LIP:LAP ratio and TGFb resistance is apparent
within these primary breast cancer cells. A high LIP:LAP ratio
in human breast carcinomas correlates with a poorly differenti-
ated phenotype of poor prognosis (Milde-Langosch et al.,
2003; Raught et al., 1996; Zahnow et al., 1997). Mouse mam-
mary tumors contain high levels of LIP (Zahnow et al., 2001),
and overexpression of a LIP transgene in the mammary epithe-
lium can cause hyperplasia (Zahnow et al., 2001). A loss of TGFb
tumor-suppressive function in LIP-rich tumors could partly
account for these previous observations.
The central role of C/EBPb in TGFb-induced cytostasis and its
malfunction in breast cancer may in turn be linked to phenom-
ena of cell senescence under oncogenic stress. When we over-
expressed LAP2 in two LIP-rich breast cancer cell samples, the
cells underwent a decrease in proliferation that was partial in
one sample and nearly complete with features of cell senes-
cence in another. It has been reported that TGFb signaling
and Smad function are required for Ras-induced senescence
in keratinocytes (Tremain et al., 2000; Vijayachandra et al.,
2003), whereas C/EBPb has been shown to mediate Ras-
induced senescence by acting downstream or independently
of the ARF-p53 pathway (Sebastian et al., 2005). TheseCANCER CELL SEPTEMBER 2006
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here uncovered.
In sum, our results establish a mechanistic link between
C/EBPb and TGFb cytostatic gene responses in epithelial cells,
and how disruption of this link may be at play in certain meta-
static breast cancers. Studies with larger groups of patients
are needed in order to establish the prevalence of TGFb resis-
tance in advanced breast cancer and the extent to which this re-
sistance would be caused by a high LIP:LAP ratio. Our results
also suggest a mechanism for how a high LIP:LAP ratio could
contribute to an unfavorable evolution of breast cancers. By
canceling cytostatic TGFb gene responses, a LIP:LAP imbal-
ance may set cancer cells free to co-opt for metastasis what re-
mains of this pathway. For example, Smad-mediated induction
of CTGF and IL11 by TGFb (Kang et al., 2003b, 2005) and in-
creased production of parathyroid-related protein (Yin et al.,
1999) are implicated in breast cancer bone metastasis. As
shown here in preliminary form with patient-derived samples,
the ability to reverse this imbalance may restore TGFb tumor-
suppressive functions in breast cancer.
Experimental procedures
Cell lines, transfection, and reporter assays
HaCaT keratinocytes cells were maintained in Dulbecco’s modified Eagle’s
media (DMEM) supplemented with 10% fetal bovine serum (FBS). Cell
culture media also contained 100 U/ml penicillin/streptomycin, 2 mM L-
glutamine, and 1 mg/ml fungizone. Cell lines were transfected with DNA using
Lipofectamine following the manufacturer’s instructions (Invitrogen). Lucifer-
ase reporter assays were performed as previously described (Seoane et al.,
2001). A CMV-Renilla luciferase plasmid (Promega) was included to control
for transfection efficiency. TGFb1 (R&D Systems) was used at 100 pM.
Pleural effusion samples
Patients with metastatic breast cancer and pleural effusions who required
thoracentesis for clinical indications were eligible to participate in this IRB-
approved study. Informed consent was obtained prospectively at the time
of the pleural fluid collection. A clinicopathologic database was created by
extracting data from the patients’ medical records (Table 1). Patient identi-
fiers were removed from the samples to protect patient confidentiality as
per institutional guidelines. Collections were done under sterile conditions.
The samples received 5 U/ml of heparin and were centrifuged for 10 min at
1000 rpm at 4C. The supernatant was discarded. If the pellet was bloody,
10 ml of ACK lysis buffer (Cambrex: 10-548) was added for 5 min at room
temperature. Cells were suspended in 100 ml of PBS, centrifuged, and dec-
anted. One-tenth of the cell pellet was frozen (DMSO 10%, FBS 90%)
at280C. One-tenth was resuspended in 500 ml of PBS for cytospin analysis.
The rest of the sample underwent negative selection using immunomagnetic
beads to remove leukocytes. We used a magnetic particle concentrator
(Dynal MPC-1) and anti-CD45 beads (Panleukocyte: Dynal Biotech) and
CD15 beads (Myeloid cells: Dynal biotech), per the manufacturer’s instruc-
tions. Cells were cultured for 24 hr and then incubated with a specific epithe-
lial antibody (anti-EpCAM-APC) (Becton Dickinson) at a 1:50 dilution with
PBS and 0.01% sodium azide. Unstained cells and isotype antibody (anti-
IgG1-APC)-stained samples were used as controls. EpCAM-positive cells
were sorted using a DakoCytomation MoFlo cell sorter. All pleural effusion
cells were maintained at 5% CO2 and 37
C in M199 media (Sigma) supple-
mented with 2.5% FBS, 10 mg/ml insulin (SIGMA), 0.5 mg/ml hydrocortisone
(Sigma), 20 ng/ml epidermal growth factor (Invitrogen), 100 ng/ml cholera
toxin (Sigma), 1 mg/ml fungizone, and 100 U/ml penicillin/streptomycin. Cells
were maintained in culture for a maximum of 12 days.
Plasmids
p15SBR1, p15SBR2MutSBE, and p15SBR2Mut30box were constructed in
pE1bTATALuc vector. Vectors encoding C/EBPb and the three independent
isoforms (LAP1, LAP2, and LIP) were generously provided by U. Schibler
(University of Geneva). Human LAP2 and LIP were cloned by PCR fromCANCER CELL SEPTEMBER 2006cDNA template and then digested with EcoR1/SalI and inserted in pBabe-
Puro. Human LIP was cloned by PCR from cDNA templates and then subse-
quently digested with BamHI, inserted in pQCXIP (Clontech), and analyzed
for the right orientation. pCDNA3-C/EBPa was generously provided by P.F.
Johnson (NCI-Frederick). The C/EBPg insert was subcloned into the
EcoRI/SalI sites of a modified pCMV5 plasmid containing two copies of the
HA epitope. A retroviral construct containing a triple fusion protein reporter
construct encoding herpes simplex virus thymidine kinase 1, green fluores-
cent protein (GFP), and firefly luciferase was used as a transfection control
(Minn et al., 2005). The Del-5 c-MYC reporter construct (Chen et al., 2001)
and the p15SBR2 and Ha-FoxO constructs (Seoane et al., 2004) were
previously described.
Small interfering RNA and short hairpin RNA
siRNA duplexes targeting FoxO1, 3, and 4 were obtained from the MSKCC
High Throughput Screening Core Facility. The coding strands of the siRNA
were as follows: FoxO1, CCGCGCAAGAGCAGCTCGT, TGTGCGCCTGGA
CTCTTGA; FoxO3, GGGCGACAGCAACAGCTCT; and FoxO4, CCCGACCA
GAGATCGCTAATT. Cell lines were transfected with siRNA using Lipofect-
amine 2000 following the manufacturer’s instructions (Invitrogen).
The siRNA-expressing H1 pRetrosuper retroviral system was generously
provided by R. Bernards (Netherlands Cancer Institute) (Brummelkamp
et al., 2002). The pRetrosuper sh(C/EBPb) vector was generated by digesting
pRetrosuper with BglII and HindIII and ligating with annealed oligos. The
siRNA oligo pairs targeting C/EBPb were 50GATCCCCATCCATGGAAGTGG
CCAAC TTCAAGAGAGTTGGCCACTTCCATGGATTTTTTGGAA. The target
sequences are underlined. Ecotropic retroviral supernatants were harvested
48 hr posttransfection of Phoenix packaging cells, filtered (0.45 mM), and
then concentrated at 18,000 rpm for 2 hr and used for overnight infections
of HaCaT cells in the presence of 4 mg/ml of polybrene. After 24 hr of cul-
ture in fresh media, infected cells were selected with 5 mg/ml puromycin for
24–48 hr.
Northern blot
Cells were incubated with TGFb as indicated, and total RNA was extracted
using the Qiagen RNeasy kit. Total RNA (5 mg) was used for Northern blot
analysis. RNA was fractionated through a 1% agarose gel and transferred
to Hybond N+ nylon membranes (Amersham Pharmacia). Data were quanti-
fied with a STORM 840 scanner and Scanner Control v4.1 software (Molec-
ular Dynamics).
Immunoprecipitation and Western immunoblotting
Immunoprecipitation assays were performed in binding buffer (20 mM
HEPES [pH 7.9], 50 mM KCl, 2 mM MgCl2, 0.5 mM EDTA, 10% glycerol,
2 mMDTT, 10 mMNaF, 20 mM b-glycerophosphate, 0.05%NP-40, and pro-
tease inhibitor cocktail), using the same amount of cell extracts (1mg protein)
in all conditions. Antibodies used were anti-Smad2/3 (Kretzschmar et al.,
1999), anti-C/EBPb (C-19, Santa Cruz), and rabbit IgG (Cell Signaling).
Anti-rabbit Ig beads and rabbit IgG TrueBlot HRP-conjugated secondary
antibody (eBioscience) were used to capture immune complexes. Western
immunoblotting was performed as previously described, using the anti-
bodies listed above or anti-Smad4 antibodies (Calonge and Massague´,
1999). Band intensity was quantified with a Fujifilm LAS-3000 Imager and
Image Gauge v4.0 software (Fujifilm).
ChIP
HaCaT cells were grown to 70% confluence, incubated in the presence or
absence of TGFb for 90 min, and subsequently crosslinked with 1% formal-
dehyde at room temperature for 15 min. ChIP was performed as described
previously (Shang et al., 2000). The antibodies used were anti-Smad2/3
(Kretzschmar et al., 1999), anti-FoxO3 (Santa Cruz [H-144]), anti-Flag M2
(Sigma), anti-Myc (9E10, Santa Cruz), and anti-C/EBPb (C-19, Santa Cruz).
A 308 bp segment of the distal region of the p15INK4b promoter (nucleotides
2547 to2239) was amplifiedwith the following primers: 50-TATGGTTGACTA
ATTCAAACA-30 (sense) and 50-AATATTTTGGGAATGTTCACCA-30 (anti-
sense). In the proximal region of the p15INK4b promoter (nucleotides 2177
to 161), a 338 bp segment was amplified with the following primers: 50-AGT
CTCTGGCGCATGCGTCCTA-30 (sense) and 50-TTAGCTCCGGGCTTTTCCT
GGC-30 (antisense). A region of the c-MYC promoter (nucleotides 2206
to +196) harboring the TGFb inhibitory element (TIE) was amplified with the211
A R T I C L Efollowing primers: 50-CTTTATAATGCGAGGGTCTGGAGC-30 and 50-
GCTATGGGCAAAGTTTCGTGGATG-30. As a negative control, a 166 bp re-
gion of the b-actin promoter (nucleotides 29 to 195) was amplified with the
following primers: 50-TCGAGCCATAAAAGGCAACTT-30 (sense) and 50-
AAACTCTCCCTCCTCCTCTTCC-30 (antisense).
Retroviral infection
H29 packaging cell lines were transfected with the pRetroSuper, pBabe-
Puro, or pQCXI (Clontech) retroviral constructs using Lipofectamine following
the manufacturer’s instructions (Invitrogen). Viral supernatants were har-
vested 48 hr posttransfection, filtered (0.45 mM), and then concentrated at
18,000 rpm during 2 hr and used for overnight infections of HaCaT cells or
EpCAM+ pleural effusion cells in the presence of 8 mg/ml of polybrene. Cells
were then recovered for 24 hr with fresh media and then selected by 5 mg/ml
puromycin for 24 hr.
Cell proliferation assays
A total of 105 cells/well were plated and treated with or without daily additions
of TGFb (100 pM). Cell numbers were recorded in triplicate over a 4 day pe-
riod. 125I-deoxyuridine incorporation assays were performed as described
previously (Carcamo et al., 1995).
Quantitative real-time PCR assays
cDNA was synthesized from 1 mg of purified RNA using the SuperScript III
First-Strand Synthesis System for RT-PCR from Invitrogen following the
manufacturer’s protocol. qRT-PCR was performed using a 7900HT instru-
ment (Applied Biosystems). All reactions were performed in a volume of
10 ml containing 1 ml cDNA template (20 ng), 0.1 mM primers, and 5 ml of the
SYBR Green I Master Mix (Applied Biosystems). Each sample was analyzed
in quadruplicate. A no-template control was included for each primer set
used. PCR cycling parameters were as follows: 50C for 2 min, 95C for 10
min, and 40 cycles of 94C for 15 s, 60C for 1 min. Data analysis was
done using the comparative CT method in software SDS2.2.2 (Applied Bio-
systems).
Animal studies
All animal work was done in accordance with a protocol approved by the In-
stitutional Animal Care and Use Committee. Nude-beige (NIH-bg-nu-xidBR)
(NCI) mice 4–6 weeks old were used for all xenografting studies. For mam-
mary fat pad tumor assays, cells were harvested by trypsinization, washed
twice in PBS, and counted. Cells were then resuspended (106 cells/ml) in
a 50:50 solution of PBS and Matrigel. Mice were anesthetized, a small inci-
sion was made to reveal the mammary gland, and 105 cells were injected di-
rectly into the mammary fat pad. The incision was closed with wound clips,
and primary tumor outgrowth was monitored weekly by bioluminescent im-
aging.
Bioluminescent imaging and analysis
Mice were anesthetized and injected retro-orbitally with 1.5 mg of d-luciferin
(15 mg/ml in PBS). Imaging was completed between 2 and 5 min after injec-
tion with a Xenogen IVIS system coupled to Living Image acquisition and
analysis software (Xenogen). For BLI plots, photon flux was calculated for
each mouse by using a circle region of interest encompassing the mammary
fat pad of the mouse. This value was scaled to a comparable background
value (from a luciferin-injected mouse with no tumor cells).
Primers used for qRT-PCR
Primers were as follows: 18S, forward, CTCAACACGGGAAACCTCAC; 18S,
reverse, CGCTCCACCAACTAAGAACG; CDC42EP3, forward, AGACTCGG
CTGGATCTGC; CDC42EP3, reverse, GACCACAACCAGGACAAACC; CDK
N1A, forward, CCGAGGCACTCAGAGGAG; CDKN1A, reverse, AGCTGCTC
GCTGTCCACT; CDKN2B, forward, CAACGGAGTCAACCGTTTC; CDKN2B,
reverse, GGTGAGAGTGGCAGGGTCT; CTGF, forward, CTGCAGGCTAGA
GAAGCAGAG; CTGF, reverse, GATGCACTTTTTGCCCTTCT; GADD45A,
forward, GCCAAGCTGCTCAACGTC; GADD45A, reverse, CTGGATCAGGG
TGAAGTGG; GADD45B, forward, AGTCGGCCAAGTTGATGAAT; GADD45B,
reverse, CCTCCTCCTCCTCGTCAAT; IER3, forward, CCGCAGGGTTCTC
TACCC; IER3, reverse, GGATCTGGCAGAAGACGATG; JAG1, forward, TGC
CAAGTGCCAGGAAGT; JAG1, reverse, GCCCCATCTGGTATCACACT; LEMD3,
forward, AGGAATGAGAGGGACAGGAGT; LEMD3, reverse, TGTTTCACCA212AAGGGGTTTT; OVOL1, forward, ACAGACCCCCAGAGCAGAG; OVOL1, re-
verse, GACTGTCCCCAAGGGTCAC; PAI, forward, AAGGCACCTCTGAGAA
CTTCA; PAI, reverse, CCCAGGACTAGGCAGGTG; SGK, forward, CTGAG
CTTATGAATGCCAACC; SGK, reverse, GCCAAGGTTGATTTGCTGAG.
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